Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John G Gerber

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 28, 2005
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 StudyJohn G Gerber, Susan L Rosenkranz, Carl J Fichtenbaum, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 4, 2006
Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherenceHulin Wu, Yangxin Huang, Edward P Acosta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2003
Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials GroupMichael P Dubé, James H Stein, Judith A Aberg, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2007
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice dailyEdward P Acosta, Michelle A Kendall, John G Gerber, et al.
The Journal of Infectious Diseases|July 23, 2002
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)Arlene S Pereira, Laura M Smeaton, John G Gerber, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186John G Gerber, Douglas W Kitch, Carl J Fichtenbaum, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 6, 2009
Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavirDavid W Haas, Susan L Koletar, Laura Laughlin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 20, 2002
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panelMorris Schambelan, Constance A Benson, Andrew Carr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individualsEdward P Acosta, Hulin Wu, Scott M Hammer, et al.
HIV Clinical Trials|January 18, 2011
A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimenScott M Hammer, Heather Ribaudo, Roland Bassett, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 28, 2005
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 StudyJohn G Gerber, Susan L Rosenkranz, Carl J Fichtenbaum, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 4, 2006
Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherenceHulin Wu, Yangxin Huang, Edward P Acosta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2003
Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials GroupMichael P Dubé, James H Stein, Judith A Aberg, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2007
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice dailyEdward P Acosta, Michelle A Kendall, John G Gerber, et al.
The Journal of Infectious Diseases|July 23, 2002
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)Arlene S Pereira, Laura M Smeaton, John G Gerber, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186John G Gerber, Douglas W Kitch, Carl J Fichtenbaum, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 6, 2009
Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavirDavid W Haas, Susan L Koletar, Laura Laughlin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 20, 2002
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panelMorris Schambelan, Constance A Benson, Andrew Carr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individualsEdward P Acosta, Hulin Wu, Scott M Hammer, et al.
HIV Clinical Trials|January 18, 2011
A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimenScott M Hammer, Heather Ribaudo, Roland Bassett, et al.
Pageof 3